Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mereo BioPharma Group (MREO) Equity Ratio: 2020-2025

Historic Equity Ratio for Mereo BioPharma Group (MREO) over the last 2 years, with Sep 2025 value amounting to 0.87.

  • Mereo BioPharma Group's Equity Ratio rose 6.36% to 0.87 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.87, marking a year-over-year increase of 6.36%. This contributed to the annual value of 0.80 for FY2024, which is 5.02% up from last year.
  • Per Mereo BioPharma Group's latest filing, its Equity Ratio stood at 0.87 for Q3 2025, which was up 0.50% from 0.87 recorded in Q2 2025.
  • Over the past 5 years, Mereo BioPharma Group's Equity Ratio peaked at 0.88 during Q1 2025, and registered a low of 0.08 during Q2 2021.
  • Its 3-year average for Equity Ratio is 0.82, with a median of 0.82 in 2024.
  • Per our database at Business Quant, Mereo BioPharma Group's Equity Ratio tumbled by 92.59% in 2021 and then spiked by 559.65% in 2022.
  • Over the past 5 years, Mereo BioPharma Group's Equity Ratio (Quarterly) stood at 0.10 in 2021, then skyrocketed by 559.65% to 0.66 in 2022, then rose by 14.45% to 0.76 in 2023, then rose by 5.02% to 0.80 in 2024, then grew by 6.36% to 0.87 in 2025.
  • Its Equity Ratio stands at 0.87 for Q3 2025, versus 0.87 for Q2 2025 and 0.88 for Q1 2025.